Published in Antimicrob Agents Chemother on September 08, 2009
Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis. Antimicrob Agents Chemother (2011) 1.99
Mouse model of necrotic tuberculosis granulomas develops hypoxic lesions. J Infect Dis (2011) 1.96
Imaging Enterobacteriaceae infection in vivo with 18F-fluorodeoxysorbitol positron emission tomography. Sci Transl Med (2014) 1.94
Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis. Antimicrob Agents Chemother (2012) 1.83
Evaluation of a mouse model of necrotic granuloma formation using C3HeB/FeJ mice for testing of drugs against Mycobacterium tuberculosis. Antimicrob Agents Chemother (2012) 1.66
Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis. Antimicrob Agents Chemother (2012) 1.63
Extensively drug-resistant tuberculosis in a young child after travel to India. Lancet Infect Dis (2015) 1.59
Imaging tuberculosis with endogenous beta-lactamase reporter enzyme fluorescence in live mice. Proc Natl Acad Sci U S A (2010) 1.51
Radiologic responses in cynomolgous macaques for assessing tuberculosis chemotherapy regimens. Antimicrob Agents Chemother (2013) 1.47
Heterogeneity in tuberculosis pathology, microenvironments and therapeutic responses. Immunol Rev (2015) 1.45
Hypervirulent Mycobacterium tuberculosis strain triggers necrotic lung pathology associated with enhanced recruitment of neutrophils in resistant C57BL/6 mice. PLoS One (2017) 1.39
Evaluation of standard chemotherapy in the guinea pig model of tuberculosis. Antimicrob Agents Chemother (2010) 1.37
Infection dynamics and response to chemotherapy in a rabbit model of tuberculosis using [¹⁸F]2-fluoro-deoxy-D-glucose positron emission tomography and computed tomography. Antimicrob Agents Chemother (2012) 1.32
Acceleration of tuberculosis treatment by adjunctive therapy with verapamil as an efflux inhibitor. Am J Respir Crit Care Med (2013) 1.23
Location of intra- and extracellular M. tuberculosis populations in lungs of mice and guinea pigs during disease progression and after drug treatment. PLoS One (2011) 1.20
Early Changes by (18)Fluorodeoxyglucose positron emission tomography coregistered with computed tomography predict outcome after Mycobacterium tuberculosis infection in cynomolgus macaques. Infect Immun (2014) 1.08
White paper report of the 2011 RAD-AID Conference on International Radiology for Developing Countries: integrating multidisciplinary strategies for imaging services in the developing world. J Am Coll Radiol (2012) 1.07
Heterogeneous disease progression and treatment response in a C3HeB/FeJ mouse model of tuberculosis. Dis Model Mech (2015) 1.03
Rifapentine is not more active than rifampin against chronic tuberculosis in guinea pigs. Antimicrob Agents Chemother (2012) 0.98
Gene expression of Mycobacterium tuberculosis putative transcription factors whiB1-7 in redox environments. PLoS One (2012) 0.96
Noninvasive determination of 2-[18F]-fluoroisonicotinic acid hydrazide pharmacokinetics by positron emission tomography in Mycobacterium tuberculosis-infected mice. Antimicrob Agents Chemother (2012) 0.96
Radioiodinated DPA-713 imaging correlates with bactericidal activity of tuberculosis treatments in mice. Antimicrob Agents Chemother (2014) 0.96
Selective Inactivity of Pyrazinamide against Tuberculosis in C3HeB/FeJ Mice Is Best Explained by Neutral pH of Caseum. Antimicrob Agents Chemother (2015) 0.95
Modeling tuberculosis in nonhuman primates. Cold Spring Harb Perspect Med (2014) 0.95
Tuberculous lymphadenitis: FDG PET and CT findings in responsive and nonresponsive disease. Eur J Nucl Med Mol Imaging (2012) 0.94
Mycobacterium tuberculosis dysregulates MMP/TIMP balance to drive rapid cavitation and unrestrained bacterial proliferation. J Pathol (2014) 0.92
Pathology and immune reactivity: understanding multidimensionality in pulmonary tuberculosis. Semin Immunopathol (2015) 0.92
Noninvasive molecular imaging of tuberculosis-associated inflammation with radioiodinated DPA-713. J Infect Dis (2013) 0.89
Molecular imaging reveals a progressive pulmonary inflammation in lower airways in ferrets infected with 2009 H1N1 pandemic influenza virus. PLoS One (2012) 0.87
18-Fluorodeoxyglucose positron emission tomography for tuberculosis diagnosis and management: a case series. BMC Pulm Med (2013) 0.86
A sterilizing tuberculosis treatment regimen is associated with faster clearance of bacteria in cavitary lesions in marmosets. Antimicrob Agents Chemother (2015) 0.85
In vivo prediction of tuberculosis-associated cavity formation in rabbits. J Infect Dis (2014) 0.84
Immunometabolism within the tuberculosis granuloma: amino acids, hypoxia, and cellular respiration. Semin Immunopathol (2015) 0.84
Nuclear imaging: a powerful novel approach for tuberculosis. Nucl Med Biol (2014) 0.84
The Warburg effect in mycobacterial granulomas is dependent on the recruitment and activation of macrophages by interferon-γ. Immunology (2015) 0.84
Applications of in vivo imaging in the evaluation of the pathophysiology of viral and bacterial infections and in development of countermeasures to BSL3/4 pathogens. Mol Imaging Biol (2015) 0.83
Potential role of F18 FDG PET-CT as an imaging biomarker for the noninvasive evaluation in uncomplicated skeletal tuberculosis: a prospective clinical observational study. Eur Spine J (2014) 0.82
Imaging the evolution of reactivation pulmonary tuberculosis in mice using 18F-FDG PET. J Nucl Med (2014) 0.82
Determination of [11C]rifampin pharmacokinetics within Mycobacterium tuberculosis-infected mice by using dynamic positron emission tomography bioimaging. Antimicrob Agents Chemother (2015) 0.82
Lung and Nodal Involvement in Nontuberculous Mycobacterial Disease: PET/CT Role. Biomed Res Int (2015) 0.82
Imaging Chronic Tuberculous Lesions Using Sodium [(18)F]Fluoride Positron Emission Tomography in Mice. Mol Imaging Biol (2015) 0.81
Mouse model of pulmonary cavitary tuberculosis and expression of matrix metalloproteinase-9. Dis Model Mech (2016) 0.81
The efflux pump inhibitor timcodar improves the potency of antimycobacterial agents. Antimicrob Agents Chemother (2014) 0.80
Deficiency of double-strand DNA break repair does not impair Mycobacterium tuberculosis virulence in multiple animal models of infection. Infect Immun (2014) 0.78
Persisting positron emission tomography lesion activity and Mycobacterium tuberculosis mRNA after tuberculosis cure. Nat Med (2016) 0.77
Imaging of small-animal models of infectious diseases. Am J Pathol (2012) 0.77
Sterilizing Activity of Pyrazinamide in Combination with First-Line Drugs in a C3HeB/FeJ Mouse Model of Tuberculosis. Antimicrob Agents Chemother (2015) 0.77
Segmentation of PET images for computer-aided functional quantification of tuberculosis in small animal models. IEEE Trans Biomed Eng (2013) 0.76
Microglia activation in a pediatric rabbit model of tuberculous meningitis. Dis Model Mech (2016) 0.76
Spectinamides are effective partner agents for the treatment of tuberculosis in multiple mouse infection models. J Antimicrob Chemother (2017) 0.75
The biodistribution of 5-[18F]fluoropyrazinamide in Mycobacterium tuberculosis-infected mice determined by positron emission tomography. PLoS One (2017) 0.75
The Promise of Molecular Imaging in the Study and Treatment of Infectious Diseases. Mol Imaging Biol (2017) 0.75
Clinical and radiographic differentiation of lung nodules caused by mycobacteria and lung cancer: a case-control study. BMC Infect Dis (2015) 0.75
Correlation of Glut-1 and Glut-3 expression with F-18 FDG uptake in pulmonary inflammatory lesions. Medicine (Baltimore) (2016) 0.75
Pancreatic tuberculosis: Evaluation of therapeutic response using F-18 fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography. Indian J Nucl Med (2014) 0.75
Peripancreatic Tuberculous Lymphadenitis Diagnosed via Endoscopic Ultrasound-guided Fine-needle Aspiration and Polymerase Chain Reaction. Intern Med (2017) 0.75
Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs--worldwide, 2000-2004. MMWR Morb Mortal Wkly Rep (2006) 7.90
Ipr1 gene mediates innate immunity to tuberculosis. Nature (2005) 4.53
Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med (1992) 3.31
The role of gamma-interferon, vitamin D3 metabolites and tumour necrosis factor in the pathogenesis of tuberculosis. Immunology (1987) 2.91
Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med (2007) 2.86
Lessons from experimental Mycobacterium tuberculosis infections. Microbes Infect (2006) 2.65
Pulmonary tuberculoma evaluated by means of FDG PET: findings in 10 cases. Radiology (2000) 2.55
18-fluorodeoxyglucose positron emission tomographic imaging in the detection and monitoring of infection and inflammation. Semin Nucl Med (2002) 2.45
Applications of bioluminescence imaging to the study of infectious diseases. Cell Microbiol (2007) 2.31
Molecular imaging of lymphoid organs and immune activation by positron emission tomography with a new [18F]-labeled 2'-deoxycytidine analog. Nat Med (2008) 2.24
Weekly moxifloxacin and rifapentine is more active than the denver regimen in murine tuberculosis. Am J Respir Crit Care Med (2005) 2.21
Structure and function of mammalian facilitative sugar transporters. J Biol Chem (1993) 2.14
Imaging bacterial infections with radiolabeled 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-iodouracil. Proc Natl Acad Sci U S A (2005) 1.65
Selective increase in plasma tumor necrosis factor-alpha and concomitant clinical deterioration after initiating therapy in patients with severe tuberculosis. J Infect Dis (1998) 1.62
FDG accumulation and tumor biology. Nucl Med Biol (1998) 1.59
FDG uptake and glucose transporter subtype expressions in experimental tumor and inflammation models. J Nucl Med (2001) 1.43
Usefulness of 18F-fluorodeoxyglucose positron emission tomography for diagnosing disease activity and monitoring therapeutic response in patients with pulmonary mycobacteriosis. Eur J Nucl Med Mol Imaging (2008) 1.40
Positron emission tomography imaging in nonmalignant thoracic disorders. Semin Nucl Med (2002) 1.38
Bacterial thymidine kinase as a non-invasive imaging reporter for Mycobacterium tuberculosis in live animals. PLoS One (2009) 1.37
Biomarkers of treatment response in clinical trials of novel antituberculosis agents. Lancet Infect Dis (2007) 1.32
Monitoring therapeutic efficacy by real-time detection of Mycobacterium tuberculosis mRNA in sputum. Clin Chem (2009) 1.21
Evaluation of therapeutic response of tuberculoma using F-18 FDG positron emission tomography. Clin Nucl Med (2008) 1.17
Management and outcomes of intracranial tuberculomas developing during antituberculous therapy: case report and review. Clin Pediatr (Phila) (2005) 1.14
Augmented 18F-FDG uptake in activated monocytes occurs during the priming process and involves tyrosine kinases and protein kinase C. J Nucl Med (2004) 1.06
Induction of monocyte expression of tumor necrosis factor alpha by the 30-kD alpha antigen of Mycobacterium tuberculosis and synergism with fibronectin. J Clin Invest (1996) 0.94
Template Registration with Missing Parts: Application to the Segmentation of M. Tuberculosis Infected Lungs. Proc IEEE Int Symp Biomed Imaging (2015) 0.91
Computed tomography and bronchoscopy in endobronchial tuberculosis. Can Respir J (2003) 0.86
Community-acquired meticillin-resistant Staphylococcus aureus: an emerging threat. Lancet Infect Dis (2005) 6.85
Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet (2009) 5.30
Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Respir Crit Care Med (2003) 4.67
A postgenomic method for predicting essential genes at subsaturation levels of mutagenesis: application to Mycobacterium tuberculosis. Proc Natl Acad Sci U S A (2003) 3.70
Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med (2009) 3.57
Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. Am J Respir Crit Care Med (2004) 3.45
Fluoroquinolones, tuberculosis, and resistance. Lancet Infect Dis (2003) 3.24
Extensively drug-resistant tuberculosis. Lancet Infect Dis (2008) 3.21
Evaluation of a whole-blood interferon-gamma release assay for the detection of Mycobacterium tuberculosis infection in 2 study populations. Clin Infect Dis (2002) 3.06
Performance evaluation of the GE healthcare eXplore VISTA dual-ring small-animal PET scanner. J Nucl Med (2006) 2.98
Practical data acquisition method for human brain tumor amide proton transfer (APT) imaging. Magn Reson Med (2008) 2.93
Amide proton transfer imaging of human brain tumors at 3T. Magn Reson Med (2006) 2.87
Autoimmune hypophysitis. Endocr Rev (2005) 2.86
Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med (2007) 2.86
Survival of patients with pulmonary tuberculosis: clinical and molecular epidemiologic factors. Clin Infect Dis (2002) 2.80
Reduced immunopathology and mortality despite tissue persistence in a Mycobacterium tuberculosis mutant lacking alternative sigma factor, SigH. Proc Natl Acad Sci U S A (2002) 2.76
[18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy. J Clin Oncol (2009) 2.67
Dormancy phenotype displayed by extracellular Mycobacterium tuberculosis within artificial granulomas in mice. J Exp Med (2004) 2.46
Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP. Biochem Biophys Res Commun (2004) 2.29
Confronting multidrug-resistant tuberculosis. N Engl J Med (2012) 2.22
Weekly moxifloxacin and rifapentine is more active than the denver regimen in murine tuberculosis. Am J Respir Crit Care Med (2005) 2.21
Performance of the microscopic observation drug susceptibility assay in drug susceptibility testing for Mycobacterium tuberculosis. J Clin Microbiol (2002) 2.21
Noninvasive quantification and optimization of acute cell retention by in vivo positron emission tomography after intramyocardial cardiac-derived stem cell delivery. J Am Coll Cardiol (2009) 2.20
Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis. Antimicrob Agents Chemother (2006) 2.18
Cyclic AMP intoxication of macrophages by a Mycobacterium tuberculosis adenylate cyclase. Nature (2009) 2.13
Radiolabeled small-molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer. Clin Cancer Res (2005) 2.10
Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA). J Med Chem (2008) 2.03
Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. Cancer Res (2009) 2.03
Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer. J Nucl Med (2012) 2.00
N-[N-[(S)-1,3-Dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-L-cysteine, [18F]DCFBC: a new imaging probe for prostate cancer. Clin Cancer Res (2008) 2.00
Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis. Antimicrob Agents Chemother (2011) 1.99
Mouse model of necrotic tuberculosis granulomas develops hypoxic lesions. J Infect Dis (2011) 1.96
Mycobacterium tuberculosis ECF sigma factor sigC is required for lethality in mice and for the conditional expression of a defined gene set. Mol Microbiol (2004) 1.96
The Mycobacterium tuberculosis protein LdtMt2 is a nonclassical transpeptidase required for virulence and resistance to amoxicillin. Nat Med (2010) 1.91
Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer. Mol Imaging Biol (2015) 1.90
Potent twice-weekly rifapentine-containing regimens in murine tuberculosis. Am J Respir Crit Care Med (2006) 1.90
NAAG peptidase inhibitors and their potential for diagnosis and therapy. Nat Rev Drug Discov (2005) 1.89
Spike inference from calcium imaging using sequential Monte Carlo methods. Biophys J (2009) 1.88
Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial. Am J Respir Crit Care Med (2015) 1.86
Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis. Antimicrob Agents Chemother (2012) 1.83
Tumor-specific imaging through progression elevated gene-3 promoter-driven gene expression. Nat Med (2010) 1.81
Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer. J Med Chem (2008) 1.79
Tissue sodium concentration in human brain tumors as measured with 23Na MR imaging. Radiology (2003) 1.77
2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer. Clin Cancer Res (2011) 1.69
Genetic requirements for the survival of tubercle bacilli in primates. J Infect Dis (2010) 1.69
Perspectives of biodegradable natural polysaccharides for site-specific drug delivery to the colon. J Pharm Pharm Sci (2007) 1.69
Contribution of moxifloxacin or levofloxacin in second-line regimens with or without continuation of pyrazinamide in murine tuberculosis. Am J Respir Crit Care Med (2013) 1.65
Imaging bacterial infections with radiolabeled 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-iodouracil. Proc Natl Acad Sci U S A (2005) 1.65
Molecular epidemiology of tuberculosis in a low- to moderate-incidence state: are contact investigations enough? Emerg Infect Dis (2002) 1.64
Different strains of Mycobacterium tuberculosis cause various spectrums of disease in the rabbit model of tuberculosis. Infect Immun (2003) 1.63
Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis. Antimicrob Agents Chemother (2012) 1.63
Role of the dosR-dosS two-component regulatory system in Mycobacterium tuberculosis virulence in three animal models. Infect Immun (2008) 1.63
Designer arrays for defined mutant analysis to detect genes essential for survival of Mycobacterium tuberculosis in mouse lungs. Infect Immun (2005) 1.58
A novel copper-responsive regulon in Mycobacterium tuberculosis. Mol Microbiol (2010) 1.56
In vivo differentiation of N-acetyl aspartyl glutamate from N-acetyl aspartate at 3 Tesla. Magn Reson Med (2007) 1.55
Short report: modulation of Mycobacterium tuberculosis infection by Plasmodium in the murine model. Am J Trop Med Hyg (2004) 1.54
Fluoroquinolone resistance in patients with newly diagnosed tuberculosis. Clin Infect Dis (2003) 1.53
Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium. J Infect Dis (2012) 1.53
Self-organization in high-density bacterial colonies: efficient crowd control. PLoS Biol (2007) 1.52
Polymerized human Hb use in acute chest syndrome: a case report. Transfusion (2002) 1.51
68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer. J Med Chem (2010) 1.51
Biphasic kill curve of isoniazid reveals the presence of drug-tolerant, not drug-resistant, Mycobacterium tuberculosis in the guinea pig. J Infect Dis (2009) 1.49
The aerosol rabbit model of TB latency, reactivation and immune reconstitution inflammatory syndrome. Tuberculosis (Edinb) (2007) 1.49
Mycobacterium tuberculosis cell envelope lipids and the host immune response. Cell Microbiol (2004) 1.48
Differential gene expression in response to exposure to antimycobacterial agents and other stress conditions among seven Mycobacterium tuberculosis whiB-like genes. Antimicrob Agents Chemother (2006) 1.48
Penitentiary or penthouse condo: the tuberculous granuloma from the microbe's point of view. Cell Microbiol (2009) 1.47
Brain white matter anatomy of tumor patients evaluated with diffusion tensor imaging. Ann Neurol (2002) 1.46
ABCG2/BCRP expression modulates D-Luciferin based bioluminescence imaging. Cancer Res (2007) 1.45
Astroblastoma: radiologic-pathologic correlation and distinction from ependymoma. AJNR Am J Neuroradiol (2002) 1.44
Initial evaluation of 11C-DPA-713, a novel TSPO PET ligand, in humans. J Nucl Med (2009) 1.44
Three-dimensional amide proton transfer MR imaging of gliomas: Initial experience and comparison with gadolinium enhancement. J Magn Reson Imaging (2013) 1.43
Evidence that the Streptomyces developmental protein WhiD, a member of the WhiB family, binds a [4Fe-4S] cluster. J Biol Chem (2004) 1.42
PET imaging in prostate cancer: focus on prostate-specific membrane antigen. Curr Top Med Chem (2013) 1.42
Molecular analysis of the prokaryotic ubiquitin-like protein (Pup) conjugation pathway in Mycobacterium tuberculosis. Mol Microbiol (2010) 1.42
Attenuation of late-stage disease in mice infected by the Mycobacterium tuberculosis mutant lacking the SigF alternate sigma factor and identification of SigF-dependent genes by microarray analysis. Infect Immun (2004) 1.41
Metronidazole lacks activity against Mycobacterium tuberculosis in an in vivo hypoxic granuloma model of latency. J Infect Dis (2008) 1.40
Comparison of the 'Denver regimen' against acute tuberculosis in the mouse and guinea pig. J Antimicrob Chemother (2010) 1.40
Interactions between human glutamate carboxypeptidase II and urea-based inhibitors: structural characterization. J Med Chem (2008) 1.39
PA-824 exhibits time-dependent activity in a murine model of tuberculosis. Antimicrob Agents Chemother (2010) 1.38
"Depupylation" of prokaryotic ubiquitin-like protein from mycobacterial proteasome substrates. Mol Cell (2010) 1.37
Bacterial thymidine kinase as a non-invasive imaging reporter for Mycobacterium tuberculosis in live animals. PLoS One (2009) 1.37
Bortezomib-induced enzyme-targeted radiation therapy in herpesvirus-associated tumors. Nat Med (2008) 1.37
The rapid development of fluoroquinolone resistance in M. tuberculosis. N Engl J Med (2003) 1.37
A low molecular weight PSMA-based fluorescent imaging agent for cancer. Biochem Biophys Res Commun (2009) 1.36
Epidemiology and challenges to the elimination of global tuberculosis. Clin Infect Dis (2010) 1.36
Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis. Am J Respir Crit Care Med (2009) 1.36
Phosphate depletion: a novel trigger for Mycobacterium tuberculosis persistence. J Infect Dis (2009) 1.35